Park Medi World shares extended their bull trend for the fourth straight session during Monday morning dealings, with the stock opening upside at ₹299 and touching an intraday high of ₹300.60 on the NSE. According to LiveMint, the healthcare stock is now just ₹4.40 away from its existing record high of ₹305. The stock had previously jumped more than 8% in intraday trade on Friday, 31 July, ahead of the company's June quarter (Q1FY27) results, opening at ₹282.95 against its previous close of ₹279.10 and reaching an intraday high of ₹301.95.
Choice Institutional Equities has issued a buy rating on Park Medi World with a target price of ₹350 in its research report dated August 04, 2026. As per Moneycontrol, the brokerage firm believes the company is well-positioned for sustained long-term growth, supported by its 10,000-bed expansion vision, cluster-based expansion strategy, improving patient mix with higher private-pay contribution and accelerating ARPOB growth. The report expects Revenue/EBITDA/PAT to expand at a CAGR of 35.3%/35.3%/42.2% over FY26–29E, with consideration of one more acquisition in FY27 of approximately 300 beds.
In an exchange filing on 29 July, the company announced that its board of directors meeting is scheduled to be held on Monday, 3 August, to consider and approve the standalone and consolidated unaudited financial results of the company for the quarter ended on 30 June 2026. As reported by Mint, this meeting will mark the company's first quarterly results announcement since its listing on 17 December last year.
In a significant development announced in an exchange filing on Sunday, Park Medi World announced its foray into the Uttarakhand healthcare business, expanding its operational presence to six states across North India. This strategic expansion demonstrates the company's aggressive growth strategy and commitment to strengthening its healthcare network across key regions in India.
The company had recorded record revenue, profit, and EBITDA for Q4FY26 as well as for the entire financial year 2025-26 (FY26). According to Mint reports, for Q4FY26, the company recorded the highest-ever revenue of ₹460.40 crore, up 30% YoY. Net profit also came at record ₹76.8 crore, rising 47% YoY for the quarter, with net profit margin rising 188 bps YoY to 16.7%. Its EBITDA in Q4FY26 was the highest-ever at ₹127.4 crore, up 44% YoY, with an EBITDA margin of 27.7%, up 268 bps YoY.
For FY26, the company's revenue jumped 21% YoY to a record ₹1,679.4 crore, while net profit climbed 27% YoY to ₹273.6 crore. As reported by Mint, net profit margin for the year rose by 83 bps YoY to 16.3%. EBITDA of ₹444.3 crore, grew 20% YoY, and EBITDA margin stood at 26.5% for FY26. The company's strong financial performance across both quarters and the full year has contributed to investor confidence ahead of the upcoming results announcement.
According to Mint reports, Park Medi World shares were listed on 17 December last year at an issue price of ₹162. At the current price of ₹300.60, they are up 86% from their issue price. The stock has demonstrated consistent momentum, extending gains for four consecutive sessions ahead of the Q1 results announcement, indicating strong market confidence in the company's performance trajectory.
